Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | CPA2 | P48052 | 1/20 | 0.43 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840760 | 1.00 | REN (0.49) | RENCAPN1PSEN1PSEN2APH1B | |
| SCHEMBL3841326 | 0.89 | CAPN1 (0.52) | RENCAPN1PSEN1PSEN2APH1B | |
| SCHEMBL21458009 | 0.89 | CAPN1 (0.52) | RENCAPN1PSEN1PSEN2APH1B | |
| SCHEMBL21458081 | 0.88 | CAPN1 (0.66) | RENCAPN1PSMB1CTSKCTSL | |
| SCHEMBL21458079 | 0.88 | CAPN1 (0.66) | RENCAPN1PSMB1CTSKCTSL | |
| SCHEMBL4401138 | 0.88 | CAPN1 (0.66) | RENCAPN1PSMB1CTSKCTSL | |
| SCHEMBL3837915 | 0.84 | PSMB1 (0.50) | RENANPEPMMP3PSMB1CPA1 | |
| SCHEMBL21458026 | 0.84 | MEN1 (0.46) | RENCAPN1PSMB1 | |
| SCHEMBL30128799 | 0.83 | CTSK (0.47) | RENCAPN1PSMB1CTSKCTSS | |
| SCHEMBL3844110 | 0.82 | CAPN1 (0.64) | RENCAPN1ANPEPMMP3CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | REN 2031/4885CAPN1 4158/4885PSEN1 691/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | REN 2031/4885CAPN1 4158/4885PSEN1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.